- Women's Health
- Programs & Services
- Cost Management
- Specialty Management
- Care Management
- Member Engagement
- Health Plan Client Engagement
Gene Therapy Solutions
Keeping Costs from Mitigating Their Promising Potential.
Hundreds of gene therapies are in various stages of development for a wide range of conditions, which were previously untreatable or at least incurable. While there are only a handful of approved gene therapies today, the U.S. Food and Drug Administration anticipates it will be approving 10 to 20 cell and gene therapies annually by 2025.
Just 5,000 individuals being treated by gene therapy each year, with treatments priced at $2 million each, would add $10 billion per year to the nation’s health care bill.
|Want to learn how our solutions can help amplify your cost management?||Contact us|
|Want to learn how our solutions can help amplify your cost management?
Many of these conditions currently require lifetime care and treatment and that can be expensive, but the cost impact is spread out over a long period. With very expensive gene therapies, payors face a large one-time cost that — even accounting for only a few members needing the treatment — could put a small or self-insured employer out of business. This may lead some to exclude coverage.
Our role is to help reduce the costs of treatments, while ensuring appropriate utilization of cutting-edge therapies.
In addition to refining foundational medical and pharmacy benefit strategies, we are developing various approaches to help payors mitigate what could be a detrimental impact from a large one-time cost for gene therapy treatment for one or a few plan members.
Both products may offer clients an alternative to excluding high-cost gene therapies.
In addition to financial protection programs, there are other potentially complementary approaches health plans and employers can utilize to reduce the cost impact of gene therapies including extending a model such as Aetna’s National Medical Excellence Program to gene therapy, value-based contracting, and an evolution of the role of specialty pharmacy to encourage direct dispensing to prevent costs from increasing because of the practice known as “buy-and-bill.”
Making sure gene therapy-based treatments are accessible for all those who need them requires innovative partnerships, as well as new ways of providing health insurance and pharmacy benefit design. Without solutions to help payors manage the cost, some may make the choice to exclude coverage, which could jeopardize patient access to these potentially life-saving medications.
At CVS Health, we are designing programs for our clients that can help mitigate the cost impact and ensure better access to appropriate therapies. Such solutions, if implemented, are likely to prove extraordinarily important in helping ensure that the price of gene therapies do not prove unsustainable for our health care system.
*Stop-loss coverage is provided by Aetna Life Insurance Company and its affiliates (Aetna). Aetna is a member of the CVS Health family of companies.
©2021 CVS Health. All rights reserved. 106-54086A 022421